Spyre Therapeutics, Inc.
SYRE
株式のランク
#2473
Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical... Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclonal immunoglobulin G1 antibody specifically engineered to target and bind with the a4ß7 integrin. This particular therapy is under development for addressing both ulcerative colitis and Crohn's disease, two forms of IBD. Furthermore, Spyre Therapeutics is advancing SPY002, another human monoclonal antibody that aims to interact with tumor necrosis factor-like ligand 1A (TL1A). A synergistic approach is also being explored with SPY120, a compound that merges the anti-a4ß7 action of SPY001 with the anti-TL1A activity of SPY002. All these programs are currently undergoing preclinical evaluation. Beyond these, the company's early-stage portfolio encompasses several additional promising candidates: SPY003, an anti-IL-23 monoclonal antibody; SPY004, a monoclonal antibody with a novel mechanism of action; SPY130, which combines anti-a4ß7 and anti-IL-23 antibodies; and SPY230, a dual antibody therapy featuring anti-TL1A and anti-IL-23 components. Originally incorporated in 2013, the organization was previously known as Aeglea BioTherapeutics, Inc., before rebranding to Spyre Therapeutics, Inc. in November 2023. Its headquarters are located in Waltham, Massachusetts.
株価
$85.55
時価総額
$7.90B
変化（1日）
7.07%
変化（1年）
280.71%
国
US
取引 Spyre Therapeutics, Inc. (SYRE)
カテゴリー
Healthcare
Spyre Therapeutics, Inc.（SYRE）のEPS
June 2026 時点のEPS TTM: $-1.95
Spyre Therapeutics, Inc.の最新の財務報告と株価によると、同社の現在のEPS（TTM）は$-1.95です。2023年末には、EPSは$-46.15で、2022年のEPS$-24.86と増加でした。
Spyre Therapeutics, Inc.のEPS履歴（2014から2026まで）
各年末時点のEPS
| 年 | EPS | 変化 |
|---|---|---|
| 2026 (TTM) | $-1.95 | -38.68% |
| 2024 | $-3.18 | -93.11% |
| 2023 | $-46.15 | 85.64% |
| 2022 | $-24.86 | -0.64% |
| 2021 | $-25.02 | -33.97% |
| 2020 | $-37.89 | -38.12% |
| 2019 | $-61.23 | 14.99% |
| 2018 | $-53.25 | 18.31% |
| 2017 | $-45.01 | -18.75% |
| 2016 | $-55.40 | 124.20% |
| 2015 | $-24.71 | 30.67% |
| 2014 | $-18.91 | 0.00% |
同様の企業または競合他社のEPS
| 企業 | EPS | EPSの差 | 国 |
|---|---|---|---|
| $17.32 | -988.21% |
US
|
|
| $-7.98 | 309.23% |
US
|
|
| $-5.29 | 171.28% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -1,522.56% |
NL
|
